Theralase’s Patented Photo Dynamic Compound (PDC) Effective in Destruction of
Cancerous Tumours in Live AnimalsFOR IMMEDIATE RELEASETORONTO ONTARIO - December 1st, 2011Previously released November 29, 2011
Theralase Technologies Inc. (TSXV: TLT) announced previously that its patented light activated PDC technology was successful in destroying cancerous tumours located under the skin of a live animal. Due to overwhelming investor interest in the November 29, 2011 press release, the Company has provided this press release for further clarity on this important milestone in the history of the Company.
Roger Dumoulin-White, who is the President and CEO of Theralase Inc. stated, "Theralase is excited that our PDC technology has achieved this critical milestone because we have now validated our technology in the destruction of cancerous tumours in live animals. The Theralase PDC treatment was successful and well tolerated by the animals and as a result, this preclinical success will help the Company to identify the leading PDC to take forward for additional animal and human cancer destruction applications. Now that our PDC technology has been proven successful in the destruction of cancerous tumours in animals, this may lead to a new significant revenue stream for the Company in the destruction of cancerous tumours in companion animals and humans in the not too distant future."
About Theralase Technologies Inc. Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination.
For further information please visit www.theralase.com. regulatory filings may be viewed by visiting www.sedar.com
This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
Downloads:
Download the Press Release
For more information contact:
Roger Dumoulin-White,
President and CEO,
Theralase Technologies Inc.
416-447-8455 ext. 225
rwhite@theralase.com
Greg Bewsh
Director of Investor Relations
416-447-8455 ext. 262
gbewsh@theralase.com
Regards,
The Theralase Team
Web Sites:
www.theralase.com
Theralase Laser Clinic
Clinic Locator | 
No comments:
Post a Comment